VIR VIR BIOTECHNOLOGY INC revenue, earnings and financials

For the quarter ended June 30, 2026, VIR BIOTECHNOLOGY INC reported revenue of $239M (up 19582.5% from a year earlier), net income of $80.1M and diluted EPS of $0.47; over the last four quarters revenue was $303M and net income −$252M; for the fiscal year ended December 2025 revenue was $68.6M, down 7.6% on the year before.

VIR annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $68.6M, gross profit n/a, operating income −$479M, net income −$438M (margin -638.9%), EPS −$3.16
• Fiscal year ended Dec 2024: revenue $74.2M, gross profit n/a, operating income −$587M, net income −$522M (margin -703.4%), EPS −$3.83
• Fiscal year ended Dec 2023: revenue $86.2M, gross profit n/a, operating income −$684M, net income −$615M (margin -713.8%), EPS −$4.59
• Fiscal year ended Dec 2022: revenue $1.62B, gross profit n/a, operating income $833M, net income $516M (margin 31.9%), EPS $3.83
• Fiscal year ended Dec 2021: revenue $1.10B, gross profit n/a, operating income $421M, net income $529M (margin 48.3%), EPS $3.96

VIR quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $239M (up 19582.5% year over year), net income $80.1M, EPS $0.47
• Quarter ended Mar 31, 2026: revenue −$29.0K (down 101.0% year over year), net income −$126M, EPS −$0.85
• Quarter ended Dec 31, 2025 (from the annual report): revenue $64.1M (up 417.8% year over year), net income −$42.9M, EPS −$0.31
• Quarter ended Sep 30, 2025: revenue $240K (down 89.9% year over year), net income −$163M, EPS −$1.17
• Quarter ended Jun 30, 2025: revenue $1.21M (down 60.5% year over year), net income −$111M, EPS −$0.80
• Quarter ended Mar 31, 2025: revenue $3.03M (down 94.6% year over year), net income −$121M, EPS −$0.88
• Quarter ended Dec 31, 2024 (from the annual report): revenue $12.4M (down 26.3% year over year), net income −$105M, EPS −$0.77
• Quarter ended Sep 30, 2024: revenue $2.38M (down 9.8% year over year), net income −$214M, EPS −$1.56
• Quarter ended Jun 30, 2024: revenue $3.08M (down 19.0% year over year), net income −$138M, EPS −$1.02
• Quarter ended Mar 31, 2024: revenue $56.4M (down 10.5% year over year), net income −$65.3M, EPS −$0.48
• Quarter ended Dec 31, 2023 (from the annual report): revenue $16.8M (down 66.0% year over year), net income −$116M, EPS −$0.86
• Quarter ended Sep 30, 2023: revenue $2.64M (down 99.3% year over year), net income −$163M, EPS −$1.22
• Quarter ended Jun 30, 2023: revenue $3.80M (up 109.3% year over year), net income −$195M, EPS −$1.45
• Quarter ended Mar 31, 2023: revenue $63.0M (down 94.9% year over year), net income −$141M, EPS −$1.06
• Quarter ended Dec 31, 2022 (from the annual report): revenue $49.4M (down 93.9% year over year), net income −$102M, EPS −$0.74
• Quarter ended Sep 30, 2022: revenue $375M (up 261.5% year over year), net income $175M, EPS $1.30
• Quarter ended Jun 30, 2022: revenue −$40.6M (down 122.9% year over year), net income −$76.5M, EPS −$0.58
• Quarter ended Mar 31, 2022: revenue $1.23B (up 62271.4% year over year), net income $519M, EPS $3.85
• Quarter ended Dec 31, 2021 (from the annual report): revenue $813M, net income $525M, EPS $4.00
• Quarter ended Sep 30, 2021: revenue $104M, net income $110M, EPS $0.82

VIR cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$392M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$446M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$779M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow $1.66B, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$47.6M, share buybacks n/a

VIR balance sheet

• Jun 30, 2026: cash $279M, total assets $1.21B, total liabilities $232M, shareholders' equity $982M
• Mar 31, 2026: cash $274M, total assets $1.03B, total liabilities $213M, shareholders' equity $813M
• Dec 31, 2025: cash $232M, total assets $1.00B, total liabilities $238M, shareholders' equity $765M
• Sep 30, 2025: cash $170M, total assets $1.02B, total liabilities $223M, shareholders' equity $796M
• Jun 30, 2025: cash $211M, total assets $1.19B, total liabilities $245M, shareholders' equity $947M
• Mar 31, 2025: cash $274M, total assets $1.31B, total liabilities $264M, shareholders' equity $1.04B
• Dec 31, 2024: cash $223M, total assets $1.40B, total liabilities $248M, shareholders' equity $1.15B
• Sep 30, 2024: cash $168M, total assets $1.50B, total liabilities $258M, shareholders' equity $1.24B

What is VIR's revenue?

VIR BIOTECHNOLOGY INC reported $303M of revenue over its last four quarters, through June 30, 2026.

Is VIR profitable?

No. VIR BIOTECHNOLOGY INC lost $252M over the last four quarters.

What is VIR's EPS?

Diluted earnings per share over the last four quarters were −$1.86; $0.47 in the latest quarter.

VIR ownership and insider trades · All stocks